Results 21 to 30 of about 53,515 (238)

Severe Gastritis after Administration of Nivolumab and Ipilimumab [PDF]

open access: yesCase Reports in Oncology, 2018
Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies.
Yoshito Nishimura   +6 more
doaj   +2 more sources

Profile of ipilimumab and its role in the treatment of metastatic melanoma

open access: yesDrug Design, Development and Therapy, 2011
Sapna P Patel, Scott E WoodmanMelanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USAAbstract: Melanoma is an immunogenic cancer.
Patel SP, Woodman SE
doaj   +1 more source

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma

open access: yesCancer Management and Research, 2012
Claire VerschraegenProfessor of Medicine, Division of Hematology Oncology, University of Vermont, Vermont Cancer Center, VT, USABackground: Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor ...
Verschraegen C
doaj   +1 more source

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

open access: yesJournal for ImmunoTherapy of Cancer, 2023
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma.
Celeste Lebbe   +15 more
doaj   +1 more source

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma [PDF]

open access: yesNew England Journal of Medicine, 2015
In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment,
Michael A, Postow   +20 more
openaire   +2 more sources

Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis

open access: yesFrontiers in Oncology, 2022
Multiple treatments of unresectable advanced or metastatic melanoma have been licensed in the adjuvant setting, causing tremendous interest in developing neoadjuvant strategies for melanoma.
Mingyi Jing   +12 more
doaj   +1 more source

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma

open access: yesJournal of Skin Cancer, 2021
Background. Checkpoint inhibitors are effective in the treatment of several types of cancer, either being used separately or in combination. Ipilimumab pioneered the treatment of metastatic melanoma, and nowadays, it has been used more frequently in ...
A. A. Formozo   +3 more
doaj   +1 more source

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

open access: yesWorld Journal of Surgical Oncology, 2020
Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer ...
Jingjie Chen   +10 more
doaj   +1 more source

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma

open access: yesCancer Medicine, 2021
Background Adjuvant ipilimumab was found to improve the overall survival and reduce toxicity compared to high‐dose interferon (HDI) in patients with resected, high‐risk melanoma. However, the cost of ipilimumab is substantially higher than HDI.
Mia Salans   +3 more
doaj   +1 more source

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2020
Ipilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time‐varying clearance (CL) was
Kinjal Sanghavi   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy